ProQR Therapeutics (PRQR) Non Operating Income (2013 - 2025)
ProQR Therapeutics recorded quarterly Non Operating Income of $327335.4 in Q3 2025, up 50.61% quarter-over-quarter from $217336.3 in Q2 2025, and down 36.45% year-over-year from $515064.9 in Q3 2024.
ProQR Therapeutics' Non Operating Income history runs 13 years deep, the most recent figure standing at $327335.4 for Q3 2025.
- In Q3 2025, Non Operating Income fell 36.45% year-over-year to $327335.4; the TTM figure through Sep 2025 stood at $1.5 million (down 22.81% YoY), while the FY2021 annual figure was -$3.3 million, down 177.79% from the prior year.
- Non Operating Income came in at $327335.4 for Q3 2025 at ProQR Therapeutics, up from $217336.3 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.2 million in Q2 2022 to a low of -$3.0 million in Q2 2021.
- A 5-year average of $119191.5 and a median of $374292.8 in 2023 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income tumbled 361.03% in 2022 and soared 190.79% in 2024, its largest moves.
- ProQR Therapeutics' Non Operating Income stood at $340903.3 in 2021, then jumped by 77.16% to $603956.3 in 2022, then plunged by 34.57% to $395158.3 in 2023, then soared by 30.34% to $515064.9 in 2024, then sank by 36.45% to $327335.4 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $327335.4, $217336.3, and $478607.4 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 327,335.43 |
| Jun 30, 2025 | 217,336.26 |
| Mar 31, 2025 | 478,607.42 |
| Sep 30, 2024 | 515,064.95 |
| Jun 30, 2024 | 552,443.33 |
| Mar 31, 2024 | 530,144.54 |
| Sep 30, 2023 | 395,158.34 |
| Jun 30, 2023 | 511,794.46 |
| Mar 31, 2023 | -583,897.95 |
| Sep 30, 2022 | 603,956.32 |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | -922,561.60 |
| Dec 31, 2021 | 340,903.34 |
| Sep 30, 2021 | 313,690.43 |
| Jun 30, 2021 | -2.97 Mn |
| Mar 31, 2021 | 353,427.18 |
| Dec 31, 2020 | -2.02 Mn |
| Sep 30, 2020 | -2.18 Mn |
| Jun 30, 2020 | -767,717.71 |
| Mar 31, 2020 | 591,711.32 |
| Dec 31, 2019 | -1.04 Mn |
| Sep 30, 2019 | 1.53 Mn |
| Jun 30, 2019 | -596,652.36 |
| Mar 31, 2019 | 561,494.66 |
| Dec 31, 2018 | -146,098.74 |
| Sep 30, 2018 | -86,071.56 |
| Jun 30, 2018 | 321,036.55 |
| Mar 31, 2018 | -1.06 Mn |
| Dec 31, 2017 | 689,975.46 |
| Sep 30, 2017 | 1.02 Mn |
| Jun 30, 2017 | -1.30 Mn |
| Mar 31, 2017 | 572,123.50 |
| Dec 31, 2016 | 1.55 Mn |
| Sep 30, 2016 | -283,510.86 |
| Jun 30, 2016 | 760,405.89 |
| Mar 31, 2016 | -1.53 Mn |
| Dec 31, 2015 | 1.54 Mn |
| Sep 30, 2015 | -55,614.24 |
| Jun 30, 2015 | -2.40 Mn |
| Mar 31, 2015 | 7.89 Mn |
| Dec 31, 2014 | 3.65 Mn |
| Sep 30, 2014 | 1.94 Mn |
| Mar 31, 2014 | -86,333.03 |
| Dec 31, 2013 | 25,860.70 |
| Sep 30, 2013 | 7,950.23 |